product name
多非利特, ≥98% (HPLC)
质量水平
检测方案
≥98% (HPLC)
形式
powder
颜色
white to off-white
溶解性
DMSO: >20 mg/mL
储存温度
room temp
SMILES字符串
CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc2ccc(NS(C)(=O)=O)cc2
InChI
1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3
InChI key
IXTMWRCNAAVVAI-UHFFFAOYSA-N
基因信息
human ... KCNH2(3757)
正在寻找类似产品? 访问 产品对比指南
警示用语：
Danger
危险声明
危险分类
Aquatic Chronic 2 - Repr. 1B - STOT RE 2
WGK
nwg
闪点(°F)
Not applicable
闪点(°C)
Not applicable
João F S Carvalho et al.
Journal of medicinal chemistry, 56(7), 2828-2840 (2013-03-12)
Drug-induced blockade of the human ether-a-go-go-related gene K(+) channel (hERG) represents one of the major antitarget concerns in pharmaceutical industry. SAR studies of this ion channel have shed light on the structural requirements for hERG interaction but most importantly may
Zhiyi Yu et al.
Toxicology and applied pharmacology, 274(1), 78-86 (2013-11-10)
Drugs that block the cardiac K(+) channel encoded by the human ether-à-go-go gene (hERG) have been associated with QT interval prolongation leading to proarrhythmia, and in some cases, sudden cardiac death. Because of special structural features of the hERG K(+)
C Torp-Pedersen et al.
Expert opinion on investigational drugs, 9(11), 2695-2704 (2000-11-04)
Dofetilide is a class III anti-arrhythmic drug that has been approved for the treatment of atrial fibrillation. Two clinical studies, which enrolled 996 patients, demonstrated pharmacological conversion to sinus rhythm to occur in 30% of patients. Following pharmacological or electrical
R Al-Dashti et al.
The Canadian journal of cardiology, 17(1), 63-67 (2001-02-15)
Dofetilide is a new, pure class III antiarrhythmic agent that prolongs the refractory period and action potential duration without having beta-blocking or calcium channel-blocking properties, making it unique among established class III agents. Dofetilide is effective in converting atrial and
Oleg E Osadchii
Cardiovascular drugs and therapy, 26(6), 489-500 (2012-08-25)
Dofetilide is class III antiarrhythmic agent which prolongs cardiac action potential duration because of selective inhibition of I (Kr), the rapid component of the delayed rectifier K(+) current. Although clinical studies reported on proarrhythmic risk associated with dofetilide treatment, the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门